Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
14 déc. 2021 09h52 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, CA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology,...
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
09 juin 2021 14h30 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
17 mai 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
SINTX Technologies announces a fabric technology shown to inactivate upon contact SARS-CoV-2, the virus causing the COVID-19 pandemic
09 mars 2021 09h00 HE
|
SINTX Technologies, Inc.
Silicon nitride-embedded fabrics proved effective against inactivating SARS-CoV-2 virusThe fabrics may be suitable for many applications, including masks, surgical gowns, and air filters ...
Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
09 mars 2021 07h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
02 mars 2021 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Provides Update on Influenza A Program
19 oct. 2020 08h05 HE
|
Cocrystal Pharma, Inc.
– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain – – Company continues to advance IND-enabling studies for...